Healthy Clinical Trial
Official title:
PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram
The purpose of this study is to measure a particular protein in the brain called the
phosphodiesterase by using the imaging techniques of positron emission tomography (PET) and
magnetic resonance imaging (MRI).
...
Both basic and clinical studies have indicated that the 3', 5'-cyclic adenosine monophosphate
(cAMP) system plays critical roles in several brain diseases, particularly in mood disorders
and drug addiction. cAMP is synthesized from adenosine 5'-triphosphate (ATP) by adenylyl
cyclase and metabolized by cyclic nucleotide phosphodiesterases (PDEs). Among components of
the cAMP pathway, PDE4 appears to be critical for antidepressant effects.
4-[3-(cyclopentoxyl)-4-methoxyphenyl]-2-pyrrolidone (rolipram) is an inhibitor of PDE4. As a
positron emission tomography (PET) brain imaging agent, rolipram has good properties such as
high affinity of 1-2 nM and appropriate lipophilicity (Log P) of ~3. A rat study gave an
estimation of low radiation absorbed doses of the active enantiomer (R)-[11C]rolipram.
ciociWEge quality. Therefore, R-[11C]rolipram is a promising PET ligand. However, radiation
absorbed doses have not been estimated from human whole body imaging studies and a method to
measure binding of (R)-[11C]rolipram in human brain has not been established.
<TAB>
The purposes of this protocol are to estimate radiation absorbed doses of (R)-[11C]rolipram
by performing whole body imaging studies on healthy human subjects and also to establish an
accurate method to measure PDE4 levels in brain by performing test retest brain imaging
studies. The results of this overall study are required to apply this PET ligand in various
neurological and psychiatric disorders in the future.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |